

原著

2018年（平成30年）

*は他教室への協力

1. Abe A, Ohishi Y, Miyazaki T, Ozono K, Mochidome N, Saeki K, Nakamura M, Oda Y.

'Microcystic pattern' should be recognised as part of the morphological spectrum of solid-pseudopapillary neoplasm of the pancreas.

Histopathology. 2018 Jan;72(2):216-226.

2. Abe T, Kohashi K, Takemoto J, Kinoshita F, Eto M, Oda Y.

Clinicopathological Significance and Antitumor Effect of MPHOSPH1 in Testicular Germ Cell Tumor.

J Cancer. 2018 Oct 31;9(23):4440-4448.

3. Iura K, Kohashi K, Yasutake N, Ishii T, Maekawa A, Bekki H, Otsuka H, Yamada Y, Yamamoto H, Ohishi Y, Matsumoto Y, Iwamoto Y, Oda Y.

Cancer-testis antigens are predominantly expressed in uterine leiomyosarcoma compared with non-uterine leiomyosarcoma.

Oncol Lett. 2018 Jan;15(1):441-446.

4. Kohashi K, Yamamoto H, Yamada Y, Kinoshita I, Taguchi T, Iwamoto Y, Oda Y.

SWI/SNF Chromatin-remodeling Complex Status in SMARCB1/INI1-preserved Epithelioid Sarcoma.

Am J Surg Pathol. 2018 Mar;42(3):312-318.

5. Kumagae Y, Hirahashi M, Takizawa K, Yamamoto H, Gushima M, Esaki M, Matsumoto T, Nakamura M, Kitazono T, Oda Y.

Overexpression of MTH1 and OGG1 proteins in ulcerative colitis-associated carcinogenesis.

Oncol Lett. 2018 Aug;16(2):1765-1776.

6.Nakano K, Yamamoto H, Fujiwara M, Koga Y, Tsuruta S, Ihara E, Oki E, Nakamura M, Ogawa Y, Oda Y.

Clinicopathologic and Molecular Characteristics of Synchronous Colorectal Carcinoma With Mismatch Repair Deficiency.

Am J Surg Pathol. 2018 Feb;42(2):172-182.

7.Otsuka H, Kohashi K, Yoshimoto M, Ishihara S, Toda Y, Yamada Y, Yamamoto H, Nakashima Y, Oda Y.

Immunohistochemical evaluation of H3K27 trimethylation in malignant peripheral nerve sheath tumors.

Pathol Res Pract. 2018 Mar;214(3):417-425.

8.Saeki K, Ohishi Y, Matsuda R, Mochidome N, Miyasaka Y, Yamamoto H, Koga Y, Maehara Y, Nakamura M, Oda Y.

"Pancreatic Mucoepidermoid Carcinoma" Is not a Pancreatic Counterpart of CRTC1/3-MAML2 Fusion Gene-related Mucoepidermoid Carcinoma of the Salivary Gland, and May More Appropriately be Termed Pancreatic Adenosquamous Carcinoma With Mucoepidermoid Carcinoma-like Features.

Am J Surg Pathol. 2018 Nov;42(11):1419-1428.

9.Sato M, Yamamoto H, Hatanaka Y, Nishijima T, Jiromaru R, Yasumatsu R, Taguchi K, Masuda M, Nakagawa T, Oda Y.

Wnt/ β -catenin signal alteration and its diagnostic utility in basal cell adenoma and histologically similar tumors of the salivary gland.

Pathol Res Pract. 2018 Apr;214(4):586-592.

10.Yamada Y, Kinoshita I, Kenichi K, Yamamoto H, Iwasaki T, Otsuka H, Yoshimoto M, Ishihara S, Toda Y, Kuma Y, Setsu N, Koga Y, Honda Y, Inoue T, Yanai H, Yamashita K, Ito I, Takahashi M, Ohga S, Furue M, Nakashima Y, Oda Y.

Histopathological and genetic review of phosphaturic mesenchymal tumours, mixed connective tissue variant.

Histopathology. 2018 Feb;72(3):460-471.

11. Yamamoto H, Iwasaki T, Yamada Y, Matsumoto Y, Otsuka H, Yoshimoto M, Kohashi K, Taguchi K, Yokoyama R, Nakashima Y, Oda Y.

Diagnostic utility of histone H3.3G34 W, G34R, and G34 V mutant-specific antibodies for giant cell tumors of bone.

Hum Pathol. 2018 Mar;73:41-50.

12. Yasutake N, Ohishi Y, Taguchi K, Hiraki Y, Oya M, Oshiro Y, Mine M, Iwasaki T, Yamamoto H, Kohashi K, Sonoda K, Kato K, Oda Y.

Insulin-like growth factor II messenger RNA-binding protein-3 is an independent prognostic factor in uterine leiomyosarcoma.

Histopathology. 2018 Apr;72(5):739-748.

13.*Abe T, Nakata K, Kibe S, Mori Y, Miyasaka Y, Ohuchida K, Ohtsuka T, Oda Y, Nakamura M.

Prognostic Value of Preoperative Nutritional and Immunological Factors in Patients with Pancreatic Ductal Adenocarcinoma.

Ann Surg Oncol. 2018 Dec;25(13):3996-4003.

14.*Akamine T, Takada K, Toyokawa G, Kinoshita F, Matsubara T, Kozuma Y, Haratake N, Takamori S, Hirai F, Tagawa T, Okamoto T, Yoneshima Y, Okamoto I, Shimokawa M, Oda Y, Nakanishi Y, Maehara Y.

Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers.

Surg Oncol. 2018 Mar;27(1):88-94.

15.*Aly MYF, Mori Y, Miyasaka Y, Ohtsuka T, Sadakari Y, Nakata K, Oda Y, Shimizu S, Nakamura M.

Laparoscopic surgery for congenital biliary dilatation: a single-institution experience.

Surg Today. 2018 Jan;48(1):44-50.

16.*Bai X, Ihara E, Hirano K, Tanaka Y, Nakano K, Kita S, Iwamoto T, Ogino H, Hirano M, Oda Y, Nakamura K, Ogawa Y.

Endogenous Hydrogen Sulfide Contributes to Tone Generation in Porcine Lower Esophageal Sphincter Via Na⁺/Ca²⁺ Exchanger.

Cell Mol Gastroenterol Hepatol. 2018 Mar;5(3):209-221.

17.*Date K, Ohtsuka T, Nakamura S, Mochidome N, Mori Y, Miyasaka Y, Oda Y, Nakamura M.

Surveillance of patients with intraductal papillary mucinous neoplasm with and without pancreatectomy with special reference to the incidence of concomitant pancreatic ductal adenocarcinoma.

Surgery. 2018 Feb;163(2):291-299.

18.*Fujimoto H, Saito Y, Ohuchida K, Kawakami E, Fujiki S, Watanabe T, Ono R, Kaneko A, Takagi S, Najima Y, Hijikata A, Cui L, Ueki T, Oda Y, Hori S, Ohara O, Nakamura M, Saito T, Ishikawa F.

Deregulated Mucosal Immune Surveillance through Gut-Associated Regulatory T Cells and PD-1⁺ T Cells in Human Colorectal Cancer.

J Immunol. 2018 May 1;200(9):3291-3303.

19.*Guzman-Lepe J, Cervantes-Alvarez E, Collin de l'Hortet A, Wang Y, Mars WM, Oda Y, Bekki Y, Shimokawa M, Wang H, Yoshizumi T, Maehara Y, Bell A, Fox IJ, Takeishi K, Soto-Gutierrez A.

Liver-enriched transcription factor expression relates to chronic hepatic failure in humans.

Hepatol Commun. 2018 Mar 23;2(5):582-594.

20.*Harada A, Maehara K, Ono Y, Taguchi H, Yoshioka K, Kitajima Y, Xie Y, Sato Y, Iwasaki T, Nogami J, Okada S, Komatsu T, Semba Y, Takemoto T, Kimura H, Kurumizaka H, Ohkawa Y.

Histone H3.3 sub-variant H3mm7 is required for normal skeletal muscle regeneration.

Nat Commun. 2018 Apr 11;9(1):1400.

21.*Haratake N, Toyokawa G, Takada K, Kozuma Y, Matsubara T, Takamori S, Akamine T, Katsura M, Shoji F, Okamoto T, Oda Y, Maehara Y.

Programmed Death-Ligand 1 Expression and EGFR Mutations in Multifocal Lung Cancer.

Ann Thorac Surg. 2018 Feb;105(2):448-454.

22.*Hijikata Y, Okazaki T, Tanaka Y, Murahashi M, Yamada Y, Yamada K, Takahashi A, Inoue H, Kishimoto J, Nakanishi Y, Oda Y, Nakamura Y, Tani K.

A phase I clinical trial of RNF43 peptide-related immune cell therapy combined with low-dose cyclophosphamide in patients with advanced solid tumors.

PLoS One. 2018 Jan 2;13(1):e0187878.

23.*Inoue Y, Yamashita N, Kitao H, Tanaka K, Saeki H, Oki E, Oda Y, Tokunaga E, Maehara Y.

Clinical Significance of the Wild Type p53-Induced Phosphatase 1 Expression in Invasive Breast Cancer.

Clin Breast Cancer. 2018 Aug;18(4):e643-e650.

24.*Katsura M, Shoji F, Okamoto T, Shimamatsu S, Hirai F, Toyokawa G, Morodomi Y, Tagawa T, Oda Y, Maehara Y.

Correlation between CXCR4/CXCR7/CXCL12 chemokine axis expression and prognosis in lymph-node-positive lung cancer patients.

Cancer Sci. 2018 Jan;109(1):154-165.

25.*Kawaguchi K, Harimaya K, Matsumoto Y, Hayashida M, Okada S, Iida K, Kato G, Tsuchiya K, Doi T, Oda Y, Iwamoto Y, Nakashima Y.

Effect of cartilaginous endplates on extruded disc resorption in lumbar disc herniation.

PLoS One. 2018 Apr 17;13(4):e0195946.

26.*Kawakubo E, Matsumoto T, Yoshiya K, Yamashita S, Jogo T, Saeki H, Oki E, Furuyama T, Oda Y, Maehara Y.

BUBR1 Insufficiency Is Correlated with eNOS Reduction Experimentally In Vitro and In Vivo, and in Gastric Cancer Tissue.

Anticancer Res. 2018 Nov;38(11):6099-6106.

27.*Kawamoto M, Ozono K, Oyama Y, Yamasaki A, Oda Y, Onishi H.

The Novel Selective Pan-TRK Inhibitor ONO-7579 Exhibits Antitumor Efficacy Against Human Gallbladder Cancer In Vitro.

Anticancer Res. 2018 Apr;38(4):1979-198

28.*Kinoshita Y, Hida T, Hamasaki M, Matsumoto S, Sato A, Tsujimura T, Kawahara K, Hiroshima K, Oda Y, Nabeshima K.

A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma.

Cancer Cytopathol. 2018 Jan;126(1):54-63.

29.*Kobayashi T, Koga Y, Ishimura M, Nakashima K, Kato W, Ono H, Sonoda M, Eguchi K, Fukano R, Honjo S, Oda Y, Ohga S.

Fever and Skin Involvement at Diagnosis Predicting the Intractable Langerhans Cell Histiocytosis: 40 Case-Series in a Single Center.

J Pediatr Hematol Oncol. 2018 Apr;40(3):e148-e153.

30.*Kondo Y, Higa S, Iwasaki T, Matsumoto T, Maehara K, Harada A, Baba Y, Fujita M, Ohkawa Y.

Sensitive detection of fluorescence in western blotting by merging images.

PLoS One. 2018 Jan 19;13(1):e0191532.

31.*Korehisa S, Ikeda T, Okano S, Saeki H, Oki E, Oda Y, Hashizume M, Maehara Y.

A novel histological examination with dynamic three-dimensional reconstruction from multiple immunohistochemically stained sections of a PD-L1-positive colon cancer.

Histopathology. 2018 Mar;72(4):697-703.

32.*Korehisa S, Oki E, Iimori M, Nakaji Y, Shimokawa M, Saeki H, Okano S, Oda Y, Maehara Y.

Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.

Int J Cancer. 2018 Feb 15;142(4):822-832.

33.*Kozuma Y, Takada K, Toyokawa G, Kohashi K, Shimokawa M, Hirai F, Tagawa T, Okamoto T, Oda Y, Maehara Y.

Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma.

Eur J Cancer. 2018 Sep;101:20-29

34.*Maehara T, Mattoo H, Mahajan VS, Murphy SJ, Yuen GJ, Ishiguro N, Ohta M, Moriyama M, Saeki T, Yamamoto H, Yamauchi M, Daccache J, Kiyoshima T, Nakamura S, Stone JH, Pillai S.

The expansion in lymphoid organs of IL-4+ BATF+ T follicular helper cells is linked to IgG4 class switching in vivo.

Life Sci Alliance. 2018 Jan;1(1). pii: e201800050.

35.*Mori H, Kubo M, Kai M, Velasquez VV, Kurata K, Yamada M, Okido M, Kuroki S, Oda Y, Nakamura M.

BRCAness Combined With a Family History of Cancer Is Associated With a Poor Prognosis for Breast Cancer Patients With a High Risk of BRCA Mutations.

Clin Breast Cancer. 2018 Oct;18(5):e1217-e1227.

36.*Nishie A, Takayama Y, Asayama Y, Ishigami K, Ushijima Y, Okamoto D, Fujita N, Tsurumaru D, Togao O, Manabe T, Oki E, Kubo Y, Hida T, Hirahashi-Fujiwara M, Keupp J, Honda H.

Amide proton transfer imaging can predict tumor grade in rectal cancer.

Magn Reson Imaging. 2018 Sep;51:96-103.

37.*Ohtsuka T, Mori Y, Fujimoto T, Miyasaka Y, Nakata K, Ohuchida K, Nagai E, Oda Y, Shimizu S, Nakamura M.

Feasibility of Prophylactic Pancreatojejunostomy in Possible High-Risk Patients for Prevention of Pancreatic Fistula during Enucleation or Limited Pancreatic Resection.

Am Surg. 2018 Jan;84(1):149-153.

38.*Shiraishi D, Fujiwara Y, Horlad H, Saito Y, Iriki T, Tsuboki J, Cheng P, Nakagata N, Mizuta H, Bekki H, Nakashima Y, Oda Y, Takeya M, Komohara Y.

CD163 Is Required for Protumoral Activation of Macrophages in Human and Murine Sarcoma.

Cancer Res. 2018 Jun 15;78(12):3255-3266.

39.*Sonoda K, Yahata H, Okugawa K, Kaneki E, Ohgami T, Yasunaga M, Baba S, Oda Y, Honda H, Kato K.

Value of Intraoperative Cytological and Pathological Sentinel Lymph Node Diagnosis in Fertility-Sparing Trachelectomy for Early-Stage Cervical Cancer.

Oncology. 2018;94(2):92-98.

40.*Takada K, Toyokawa G, Azuma K, Takamori S, Jogo T, Hirai F, Tagawa T, Kawahara A, Akiba J, Okamoto I, Nakanishi Y, Oda Y, Hoshino T, Maehara Y.

Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study.

In Vivo. 2018

Nov-Dec;32(6):1541-1550.

41.*Takada K, Toyokawa G, Tagawa T, Kohashi K, Shimokawa M, Akamine T, Takamori S, Hirai F, Shoji F, Okamoto T, Oda Y, Maehara Y.

PD-L1 expression according to the EGFR status in primary lung adenocarcinoma.

Lung Cancer. 2018 Feb;116:1-6.

42.*Takada K, Toyokawa G, Tagawa T, Shimokawa M, Kohashi K, Haro A, Osoegawa A, Oda Y, Maehara Y.

Radiological Features of IDO1+/PDL1+ Lung Adenocarcinoma: A Retrospective Single-institution Study.

Anticancer Res. 2018 Sep;38(9):5295-5303.

43.*Takamori S, Takada K, Azuma K, Jogo Y, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Toyokawa G, Hirai F, Tagawa T, Okamoto I, Nakanishi Y, Kawahara A, Akiba J, Oda Y, Maehara Y.

Prognostic Impact of PD-L2 Expression and Association with PD-L1 in Patients with Small-cell Lung Cancer.

Anticancer Res. 2018 Oct;38(10):5903-5907.

44.*Takamori S, Takada K, Tagawa T, Toyokawa G, Hirai F, Yamashita N, Okamoto T, Oki E, Yoshizumi T, Oda Y, Maehara Y.

Differences in PD-L1 expression on tumor and immune cells between lung metastases and corresponding primary tumors.

Surg Oncol. 2018 Dec;27(4):637-641.

45.*Takamori S, Takada K, Toyokawa G, Azuma K, Shimokawa M, Jogo T, Yamada Y, Hirai F, Tagawa T, Kawahara A, Akiba J, Okamoto I, Nakanishi Y, Oda Y, Hoshino T, Maehara Y. PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer.

Anticancer Res. 2018 Oct;38(10):5897-5901.

46.*Takamori S, Toyokawa G, Okamoto T, Shimokawa M, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Takada K, Katsura M, Hirai F, Shoji F, Tagawa T, Oda Y, Honda H, Maehara Y.

Clinical Impact and Risk Factors for Skeletal Muscle Loss After Complete Resection of Early Non-small Cell Lung Cancer.

Ann Surg Oncol. 2018 May;25(5):1229-1236.

47.*Takamori S, Toyokawa G, Okamoto I, Takada K, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Mukae N, Hirai F, Tagawa T, Oda Y, Iwaki T, Iihara K, Nakanishi Y, Maehara Y.

Clinical Significance of PD-L1 Expression in Brain Metastases from Non-small Cell Lung Cancer.

Anticancer Res. 2018 Jan;38(1):553-557.

48.*Takamori S, Toyokawa G, Shimokawa M, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Mukae N, Hirai F, Tagawa T, Oda Y, Iwaki T, Iihara K, Honda H, Maehara Y.

Radiological Features of Brain Metastases from Non-small Cell Lung Cancer Harboring EGFR Mutation.

Anticancer Res. 2018 Jun;38(6):3731-3734.

49.*Takayama Y, Nishie A, Togao O, Asayama Y, Ishigami K, Ushijima Y, Okamoto D, Fujita N, Sonoda K, Hida T, Ohishi Y, Keupp J, Honda H.

Amide Proton Transfer MR Imaging of Endometrioid Endometrial Adenocarcinoma: Association with Histologic Grade.

Radiology. 2018 Mar;286(3):909-917.

50.*Tanaka K, Yanagihara T, Ikematsu Y, Inoue H, Ota K, Kashiwagi E, Suzuki K, Hamada N, Takeuchi A, Tatsugami K, Eto M, Ijichi K, Oda Y, Otsubo K, Yoneshima Y, Iwama E, Nakanishi Y, Okamoto I.

Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade.

Oncotarget. 2018 Jul 17;9(55):30587-30593.

51.*Taniguchi D, Saeki H, Nakashima Y, Kudou K, Nakanishi R, Kubo N, Ando K, Oki E, Oda Y, Maehara Y.

CD44v9 is associated with epithelial-mesenchymal transition and poor outcomes in esophageal squamous cell carcinoma.

Cancer Med. 2018 Dec;7(12):6258-6268.

52.*Torata N, Kubo M, Miura D, Ohuchida K, Mizuuchi Y, Fujimura Y, Hayakawa E, Kai M, Oda Y, Mizumoto K, Hashizume M, Nakamura M.

Visualizing Energy Charge in Breast Carcinoma Tissues by MALDI Mass-spectrometry Imaging Profiles of Low-molecular-weight Metabolites.

Anticancer Res. 2018 Jul;38(7):4267-4272.

53.*Toyokawa G, Takada K, Tagawa T, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Takamori S, Akamine T, Hirai F, Yamada Y, Hamamoto R, Oda Y, Maehara Y.
Prevalence of Enhancer of Zeste Homolog 2 in Patients with Resected Small Cell Lung Cancer.

Anticancer Res. 2018 Jun;38(6):3707-3711.

54.*Toyokawa G, Yamada Y, Tagawa T, Kamitani T, Yamasaki Y, Shimokawa M, Oda Y, Maehara Y.

Computed tomography features of resected lung adenocarcinomas with spread through air spaces.

Thorac Cancer. 2018 Oct;9(10):1255-1261.

55.*Toyokawa G, Yamada Y, Tagawa T, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Takamori S, Akamine T, Hirai F, Oda Y, Maehara Y.

High Frequency of Spread Through Air Spaces in Resected Small Cell Lung Cancer.

Anticancer Res. 2018

Mar;38(3):1821-1825.

56.*Toyokawa G, Yamada Y, Tagawa T, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Takamori S, Akamine T, Hirai F, Oda Y, Maehara Y.

Significance of Spread Through Air Spaces in Resected Lung Adenocarcinomas With Lymph Node Metastasis.

Clin Lung Cancer. 2018 Sep;19(5):395-400.e1.

57.*Toyokawa G, Yamada Y, Tagawa T, Kozuma Y, Matsubara T, Haratake N, Takamori S, Akamine T, Oda Y, Maehara Y.

Significance of Spread Through Air Spaces in Resected Pathological Stage I Lung Adenocarcinoma.

Ann Thorac Surg. 2018 Jun;105(6):1655-1663.

58.*Toyokawa G, Yamada Y, Tagawa T, Oda Y.

Significance of spread through air spaces in early-stage lung adenocarcinomas undergoing limited resection.

Thorac Cancer. 2018 Oct;9(10):1255-1261.

59.*Yahata H, Kobayashi H, Sonoda K, Kodama K, Yagi H, Yasunaga M, Ohgami T, Onoyama I, Kaneki E, Okugawa K, Baba S, Isoda T, Ohishi Y, Oda Y, Kato K.

Prognostic outcome and complications of sentinel lymph node navigation surgery for early-stage cervical cancer.

Int J Clin Oncol. 2018 Dec;23(6):1167-1172.

60.*Yahiro K, Matsumoto Y, Fukushi JI, Kawaguchi KI, Endo M, Setsu N, Iida K, Fukushima S, Nakagawa M, Kimura A, Oda Y, Nakashima Y.

Class III β -Tubulin Overexpression Induces Chemoresistance to Eribulin in a Leiomyosarcoma Cell Line.

Anal Cell Pathol (Amst). 2018 Jun 21;2018:8987568.

61.*Yamashita K, Kohashi K, Yamada Y, Ishii T, Nishida Y, Urakawa H, Ito I, Takahashi M, Inoue T, Ito M, Ohara Y, Oda Y, Toyokuni S.

Osteogenic differentiation in dedifferentiated liposarcoma: a study of 36 cases in comparison to the cases without ossification.

Histopathology. 2018 Apr;72(5):729-738.

62.*Yoneshima Y, Ijichi K, Anai S, Ota K, Otsubo K, Iwama E, Tanaka K, Oda Y, Nakanishi Y, Okamoto I.

PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements.

Lung Cancer. 2018 Apr;118:36-40.

63.*Yoshida Y, Nobusawa S, Nakata S, Nakada M, Arakawa Y, Mineharu Y, Sugita Y, Yoshioka T, Araki A, Sato Y, Takeshima H, Okada M, Nishi A, Yamazaki T, Kohashi K, Oda Y, Hirato J, Yokoo H.

CNS high-grade neuroepithelial tumor with BCOR internal tandem duplication: a comparison with its counterparts in the kidney and soft tissue.

64.*本郷貴大、中野貴史、打田義則、力丸文秀、藤賢史、檜垣雄一郎、田口健一、益田宗幸
頭頸部筋上皮癌 9 例の臨床的検討

日本耳鼻咽喉科学会会報. 2018 Nov;121(11):1366-1372